Peter Mourani
Concepts (449)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bronchopulmonary Dysplasia | 23 | 2021 | 70 | 6.600 |
Why?
| Hypertension, Pulmonary | 13 | 2023 | 114 | 3.950 |
Why?
| Intensive Care Units, Pediatric | 30 | 2024 | 169 | 3.560 |
Why?
| Cardiopulmonary Resuscitation | 18 | 2024 | 133 | 3.370 |
Why?
| Heart Arrest | 18 | 2024 | 149 | 3.370 |
Why?
| Critical Illness | 23 | 2024 | 288 | 2.550 |
Why?
| Respiration, Artificial | 18 | 2024 | 274 | 2.430 |
Why?
| Child | 93 | 2024 | 6847 | 2.360 |
Why?
| Infant, Premature | 17 | 2021 | 318 | 2.180 |
Why?
| Prospective Studies | 47 | 2024 | 2364 | 2.150 |
Why?
| Shock, Septic | 12 | 2024 | 78 | 2.010 |
Why?
| Pneumonia, Ventilator-Associated | 3 | 2021 | 19 | 2.010 |
Why?
| Lung | 10 | 2024 | 486 | 1.890 |
Why?
| Sepsis | 12 | 2023 | 220 | 1.860 |
Why?
| Infant, Newborn | 43 | 2024 | 2772 | 1.750 |
Why?
| Respiratory Tract Infections | 5 | 2024 | 75 | 1.640 |
Why?
| Respiratory Insufficiency | 5 | 2021 | 113 | 1.610 |
Why?
| Infant | 49 | 2024 | 3567 | 1.570 |
Why?
| Trachea | 3 | 2017 | 52 | 1.510 |
Why?
| Child, Preschool | 42 | 2024 | 3871 | 1.490 |
Why?
| Humans | 134 | 2024 | 49974 | 1.450 |
Why?
| Vascular Diseases | 5 | 2020 | 75 | 1.310 |
Why?
| Critical Care | 6 | 2021 | 213 | 1.250 |
Why?
| Influenza, Human | 9 | 2023 | 84 | 1.240 |
Why?
| Quality of Life | 13 | 2024 | 836 | 1.190 |
Why?
| Premature Birth | 4 | 2021 | 147 | 1.150 |
Why?
| Heart Ventricles | 2 | 2021 | 249 | 1.090 |
Why?
| Intensive Care Units | 10 | 2024 | 222 | 1.080 |
Why?
| Ventricular Dysfunction, Right | 3 | 2022 | 27 | 1.080 |
Why?
| Intubation, Intratracheal | 4 | 2024 | 118 | 1.050 |
Why?
| Male | 64 | 2024 | 25241 | 1.030 |
Why?
| Female | 67 | 2024 | 26472 | 1.000 |
Why?
| Adolescent | 41 | 2024 | 6356 | 0.990 |
Why?
| RNA, Ribosomal, 16S | 4 | 2021 | 113 | 0.940 |
Why?
| Echocardiography | 7 | 2021 | 378 | 0.920 |
Why?
| Patient Discharge | 12 | 2024 | 320 | 0.920 |
Why?
| Ventricular Function, Right | 2 | 2021 | 37 | 0.900 |
Why?
| Noninvasive Ventilation | 1 | 2024 | 21 | 0.900 |
Why?
| Respiratory Syncytial Virus Infections | 3 | 2019 | 36 | 0.840 |
Why?
| Tobacco Smoke Pollution | 1 | 2023 | 48 | 0.830 |
Why?
| Risk Factors | 20 | 2022 | 3613 | 0.750 |
Why?
| Patient Readmission | 3 | 2024 | 219 | 0.730 |
Why?
| Aftercare | 5 | 2024 | 75 | 0.710 |
Why?
| Epinephrine | 4 | 2024 | 96 | 0.690 |
Why?
| Retrospective Studies | 27 | 2024 | 6108 | 0.660 |
Why?
| Respiratory Tract Diseases | 1 | 2019 | 24 | 0.660 |
Why?
| Gestational Age | 7 | 2021 | 421 | 0.630 |
Why?
| Lung Diseases | 2 | 2010 | 92 | 0.620 |
Why?
| Nitric Oxide | 6 | 2022 | 253 | 0.610 |
Why?
| Echocardiography, Doppler | 3 | 2018 | 53 | 0.600 |
Why?
| Nutritional Support | 1 | 2017 | 34 | 0.600 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 33 | 0.600 |
Why?
| Bacteria | 4 | 2022 | 224 | 0.590 |
Why?
| Coinfection | 3 | 2022 | 38 | 0.570 |
Why?
| Energy Intake | 1 | 2017 | 170 | 0.570 |
Why?
| Respiratory Syncytial Viruses | 2 | 2013 | 12 | 0.550 |
Why?
| Energy Metabolism | 1 | 2017 | 282 | 0.520 |
Why?
| Echocardiography, Doppler, Pulsed | 1 | 2015 | 8 | 0.520 |
Why?
| Oxygen | 4 | 2024 | 326 | 0.510 |
Why?
| Oxygen Inhalation Therapy | 1 | 2015 | 18 | 0.500 |
Why?
| Myocardial Contraction | 1 | 2015 | 105 | 0.490 |
Why?
| Pulmonary Artery | 3 | 2011 | 145 | 0.490 |
Why?
| Chlorides | 3 | 2020 | 50 | 0.490 |
Why?
| Practice Guidelines as Topic | 1 | 2017 | 449 | 0.490 |
Why?
| Venous Thromboembolism | 2 | 2012 | 68 | 0.480 |
Why?
| Paramyxoviridae Infections | 1 | 2013 | 3 | 0.470 |
Why?
| Ventricular Function, Left | 1 | 2015 | 154 | 0.470 |
Why?
| Metapneumovirus | 1 | 2013 | 5 | 0.470 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2014 | 27 | 0.460 |
Why?
| Acute Kidney Injury | 4 | 2021 | 284 | 0.460 |
Why?
| Natriuretic Peptide, Brain | 1 | 2014 | 29 | 0.460 |
Why?
| Pulmonary Embolism | 2 | 2012 | 97 | 0.450 |
Why?
| Ventricular Dysfunction, Left | 2 | 2020 | 91 | 0.450 |
Why?
| Bacterial Infections | 3 | 2023 | 95 | 0.450 |
Why?
| Peripheral Vascular Diseases | 1 | 2013 | 21 | 0.440 |
Why?
| Cohort Studies | 13 | 2022 | 1422 | 0.440 |
Why?
| Quality Improvement | 3 | 2022 | 208 | 0.440 |
Why?
| Bereavement | 2 | 2021 | 8 | 0.390 |
Why?
| Denys-Drash Syndrome | 1 | 2011 | 3 | 0.390 |
Why?
| Influenza A virus | 3 | 2020 | 17 | 0.390 |
Why?
| Vasodilator Agents | 3 | 2021 | 96 | 0.390 |
Why?
| Embolectomy | 1 | 2011 | 13 | 0.390 |
Why?
| Wilms Tumor | 1 | 2011 | 18 | 0.390 |
Why?
| Research Design | 4 | 2022 | 344 | 0.370 |
Why?
| Health Resources | 5 | 2024 | 75 | 0.360 |
Why?
| Milrinone | 2 | 2021 | 9 | 0.360 |
Why?
| Pregnancy | 10 | 2024 | 2607 | 0.360 |
Why?
| Time Factors | 10 | 2024 | 2903 | 0.360 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 76 | 0.350 |
Why?
| Logistic Models | 6 | 2019 | 888 | 0.350 |
Why?
| Follow-Up Studies | 8 | 2021 | 2182 | 0.340 |
Why?
| Kidney Neoplasms | 1 | 2011 | 177 | 0.340 |
Why?
| Water-Electrolyte Imbalance | 2 | 2020 | 15 | 0.330 |
Why?
| Administration, Inhalation | 5 | 2022 | 107 | 0.330 |
Why?
| Anti-Bacterial Agents | 4 | 2024 | 744 | 0.330 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2008 | 23 | 0.330 |
Why?
| Sulfones | 1 | 2008 | 24 | 0.320 |
Why?
| Coronary Care Units | 2 | 2018 | 8 | 0.320 |
Why?
| Multiple Organ Failure | 3 | 2023 | 47 | 0.320 |
Why?
| Infant, Extremely Premature | 2 | 2020 | 35 | 0.320 |
Why?
| Heart Diseases | 2 | 2023 | 206 | 0.320 |
Why?
| Longitudinal Studies | 4 | 2020 | 688 | 0.310 |
Why?
| United States | 12 | 2024 | 4860 | 0.310 |
Why?
| Hernia, Diaphragmatic | 1 | 2008 | 22 | 0.310 |
Why?
| Staphylococcal Infections | 2 | 2022 | 268 | 0.310 |
Why?
| Heparitin Sulfate | 2 | 2024 | 9 | 0.300 |
Why?
| Hospital Mortality | 8 | 2023 | 409 | 0.300 |
Why?
| Piperazines | 1 | 2008 | 117 | 0.300 |
Why?
| Metagenomics | 4 | 2023 | 38 | 0.300 |
Why?
| Staphylococcus | 2 | 2017 | 35 | 0.290 |
Why?
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 287 | 0.280 |
Why?
| Length of Stay | 4 | 2020 | 619 | 0.280 |
Why?
| Age Factors | 6 | 2021 | 1087 | 0.280 |
Why?
| Wounds and Injuries | 2 | 2021 | 276 | 0.280 |
Why?
| Parents | 4 | 2021 | 314 | 0.280 |
Why?
| Adult | 12 | 2024 | 13236 | 0.270 |
Why?
| Young Adult | 9 | 2022 | 3958 | 0.270 |
Why?
| Treatment Outcome | 11 | 2022 | 5141 | 0.270 |
Why?
| Pregnancy in Diabetics | 2 | 2024 | 31 | 0.260 |
Why?
| Muscle, Smooth, Vascular | 2 | 2004 | 130 | 0.260 |
Why?
| Diastole | 3 | 2019 | 69 | 0.240 |
Why?
| Pneumonia, Bacterial | 1 | 2024 | 27 | 0.240 |
Why?
| Magnetic Resonance Imaging | 2 | 2023 | 1537 | 0.240 |
Why?
| Heart Failure | 2 | 2021 | 458 | 0.240 |
Why?
| Hypertrophy, Left Ventricular | 1 | 2024 | 39 | 0.240 |
Why?
| Hypercapnia | 1 | 2024 | 16 | 0.240 |
Why?
| Bradycardia | 1 | 2024 | 36 | 0.240 |
Why?
| Ribosomal Protein S6 | 1 | 2004 | 1 | 0.240 |
Why?
| Caregivers | 3 | 2021 | 208 | 0.240 |
Why?
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 16 | 0.240 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2004 | 24 | 0.240 |
Why?
| Skin Pigmentation | 1 | 2024 | 11 | 0.230 |
Why?
| Tunica Intima | 1 | 2004 | 54 | 0.230 |
Why?
| Receptors, Immunologic | 2 | 2022 | 37 | 0.230 |
Why?
| Genetic Predisposition to Disease | 3 | 2019 | 510 | 0.230 |
Why?
| Respiration | 1 | 2024 | 97 | 0.230 |
Why?
| Myocytes, Smooth Muscle | 1 | 2004 | 86 | 0.230 |
Why?
| Protein Kinases | 1 | 2004 | 71 | 0.220 |
Why?
| Proto-Oncogene Proteins | 1 | 2004 | 149 | 0.220 |
Why?
| Oximetry | 1 | 2024 | 67 | 0.220 |
Why?
| Cotinine | 1 | 2023 | 22 | 0.220 |
Why?
| Smoke | 1 | 2023 | 18 | 0.220 |
Why?
| Colorado | 4 | 2017 | 21 | 0.220 |
Why?
| Pneumonia, Staphylococcal | 1 | 2022 | 6 | 0.210 |
Why?
| Hypotension | 1 | 2023 | 63 | 0.210 |
Why?
| Socioeconomic Factors | 3 | 2020 | 581 | 0.210 |
Why?
| Reproducibility of Results | 4 | 2020 | 1193 | 0.210 |
Why?
| Sodium | 1 | 2022 | 92 | 0.210 |
Why?
| Glasgow Coma Scale | 4 | 2023 | 46 | 0.210 |
Why?
| Hospitalization | 4 | 2023 | 652 | 0.210 |
Why?
| Respiratory Syncytial Virus, Human | 1 | 2022 | 7 | 0.210 |
Why?
| Meconium Aspiration Syndrome | 1 | 2022 | 2 | 0.210 |
Why?
| Communicable Diseases | 1 | 2022 | 55 | 0.200 |
Why?
| Multivariate Analysis | 4 | 2018 | 577 | 0.200 |
Why?
| Shock | 1 | 2022 | 35 | 0.200 |
Why?
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 31 | 0.200 |
Why?
| Central Venous Catheters | 1 | 2022 | 26 | 0.200 |
Why?
| Blood Pressure | 4 | 2023 | 512 | 0.200 |
Why?
| Extremities | 1 | 2021 | 30 | 0.200 |
Why?
| Diabetes, Gestational | 1 | 2022 | 53 | 0.190 |
Why?
| Spinal Injuries | 1 | 2021 | 14 | 0.190 |
Why?
| Multiple Trauma | 1 | 2021 | 32 | 0.190 |
Why?
| Prone Position | 1 | 2021 | 29 | 0.190 |
Why?
| Iloprost | 1 | 2021 | 4 | 0.190 |
Why?
| Central Venous Pressure | 1 | 2021 | 7 | 0.190 |
Why?
| Abdominal Injuries | 1 | 2021 | 36 | 0.190 |
Why?
| Epoprostenol | 1 | 2021 | 20 | 0.190 |
Why?
| Pulmonary Circulation | 2 | 2015 | 33 | 0.190 |
Why?
| Patient Positioning | 1 | 2021 | 32 | 0.190 |
Why?
| Thoracic Injuries | 1 | 2021 | 35 | 0.190 |
Why?
| Capnography | 1 | 2021 | 17 | 0.190 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 181 | 0.190 |
Why?
| Catheterization, Central Venous | 1 | 2022 | 86 | 0.190 |
Why?
| Pneumonia | 1 | 2022 | 118 | 0.190 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2021 | 53 | 0.190 |
Why?
| Nervous System Diseases | 1 | 2022 | 88 | 0.190 |
Why?
| Proteomics | 3 | 2020 | 329 | 0.190 |
Why?
| Radiography, Thoracic | 1 | 2021 | 65 | 0.180 |
Why?
| Vasopressins | 1 | 2021 | 39 | 0.180 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 54 | 0.180 |
Why?
| Cardiac Surgical Procedures | 1 | 2023 | 297 | 0.180 |
Why?
| Chronic Disease | 3 | 2022 | 567 | 0.180 |
Why?
| Angiogenic Proteins | 1 | 2020 | 6 | 0.180 |
Why?
| Morbidity | 4 | 2022 | 133 | 0.180 |
Why?
| Medicine | 1 | 2020 | 56 | 0.180 |
Why?
| Severity of Illness Index | 5 | 2020 | 945 | 0.180 |
Why?
| Medical Audit | 1 | 2020 | 21 | 0.180 |
Why?
| Incidence | 3 | 2024 | 1003 | 0.180 |
Why?
| Hemodynamics | 3 | 2023 | 228 | 0.170 |
Why?
| Academic Medical Centers | 2 | 2017 | 144 | 0.170 |
Why?
| Muscular Dystrophy, Duchenne | 1 | 2020 | 18 | 0.170 |
Why?
| Toll-Like Receptor 4 | 1 | 2020 | 48 | 0.170 |
Why?
| Medical Records | 1 | 2020 | 83 | 0.170 |
Why?
| Mannose-Binding Lectin | 1 | 2019 | 2 | 0.170 |
Why?
| Signal Transduction | 2 | 2020 | 1618 | 0.170 |
Why?
| Motivation | 1 | 2021 | 273 | 0.170 |
Why?
| Drug Resistance, Bacterial | 1 | 2019 | 71 | 0.170 |
Why?
| Tertiary Care Centers | 1 | 2019 | 77 | 0.170 |
Why?
| Mothers | 2 | 2022 | 249 | 0.160 |
Why?
| Cardiotonic Agents | 1 | 2019 | 66 | 0.160 |
Why?
| Hyperglycemia | 1 | 2019 | 79 | 0.160 |
Why?
| Respiratory System | 1 | 2018 | 26 | 0.160 |
Why?
| Mutation, Missense | 1 | 2019 | 105 | 0.160 |
Why?
| RNA, Bacterial | 2 | 2024 | 58 | 0.160 |
Why?
| MicroRNAs | 1 | 2022 | 353 | 0.160 |
Why?
| Fibroblasts | 1 | 2020 | 345 | 0.160 |
Why?
| Cardiopulmonary Bypass | 1 | 2018 | 91 | 0.160 |
Why?
| Medical Staff, Hospital | 1 | 2018 | 14 | 0.160 |
Why?
| Inservice Training | 1 | 2018 | 30 | 0.150 |
Why?
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 1 | 0.150 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 169 | 0.150 |
Why?
| Calorimetry, Indirect | 1 | 2017 | 25 | 0.150 |
Why?
| Chorioamnionitis | 1 | 2017 | 15 | 0.150 |
Why?
| Renal Replacement Therapy | 1 | 2018 | 29 | 0.150 |
Why?
| Aged | 4 | 2024 | 9310 | 0.150 |
Why?
| Metabolomics | 1 | 2018 | 126 | 0.150 |
Why?
| Survival Rate | 4 | 2024 | 894 | 0.150 |
Why?
| Computational Biology | 1 | 2019 | 214 | 0.150 |
Why?
| Risk Assessment | 5 | 2018 | 1259 | 0.150 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2017 | 22 | 0.150 |
Why?
| Intensive Care Units, Neonatal | 1 | 2018 | 115 | 0.150 |
Why?
| Drug Administration Schedule | 2 | 2024 | 376 | 0.150 |
Why?
| Physicians | 1 | 2021 | 233 | 0.150 |
Why?
| Hypoglycemic Agents | 1 | 2019 | 168 | 0.150 |
Why?
| Delirium | 1 | 2018 | 49 | 0.150 |
Why?
| Infant, Very Low Birth Weight | 1 | 2017 | 48 | 0.150 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2018 | 349 | 0.150 |
Why?
| Tandem Mass Spectrometry | 1 | 2018 | 236 | 0.150 |
Why?
| Pre-Eclampsia | 1 | 2017 | 55 | 0.150 |
Why?
| Respiratory Distress Syndrome, Newborn | 1 | 2017 | 52 | 0.140 |
Why?
| Needs Assessment | 1 | 2017 | 133 | 0.140 |
Why?
| Transcriptome | 3 | 2024 | 315 | 0.140 |
Why?
| Observer Variation | 1 | 2017 | 130 | 0.140 |
Why?
| Smoking | 2 | 2018 | 511 | 0.140 |
Why?
| Hypertension | 2 | 2019 | 533 | 0.140 |
Why?
| Infant, Low Birth Weight | 2 | 2015 | 62 | 0.140 |
Why?
| Birth Weight | 1 | 2017 | 120 | 0.140 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2021 | 360 | 0.140 |
Why?
| RNA-Binding Proteins | 1 | 2017 | 123 | 0.140 |
Why?
| Delphi Technique | 3 | 2020 | 46 | 0.140 |
Why?
| Pneumonia, Viral | 1 | 2019 | 168 | 0.140 |
Why?
| Patient Care Team | 1 | 2018 | 254 | 0.140 |
Why?
| Blood Glucose | 2 | 2019 | 439 | 0.140 |
Why?
| Hospitals, Pediatric | 3 | 2023 | 239 | 0.130 |
Why?
| Endothelium-Dependent Relaxing Factors | 1 | 2015 | 4 | 0.130 |
Why?
| Organ Dysfunction Scores | 3 | 2020 | 17 | 0.130 |
Why?
| Trauma Centers | 3 | 2022 | 193 | 0.130 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2017 | 186 | 0.130 |
Why?
| Medical Informatics | 1 | 2016 | 49 | 0.130 |
Why?
| Prognosis | 4 | 2023 | 1942 | 0.130 |
Why?
| Indiana | 1 | 2015 | 16 | 0.130 |
Why?
| Membrane Proteins | 1 | 2017 | 341 | 0.120 |
Why?
| Diabetic Ketoacidosis | 1 | 2014 | 18 | 0.120 |
Why?
| Hypokalemia | 1 | 2014 | 10 | 0.120 |
Why?
| Schools, Medical | 1 | 2015 | 69 | 0.120 |
Why?
| Hyperoxia | 2 | 2024 | 26 | 0.120 |
Why?
| Tomography, X-Ray Computed | 1 | 2019 | 1159 | 0.120 |
Why?
| Bronchiolitis, Viral | 1 | 2013 | 7 | 0.120 |
Why?
| Risk | 2 | 2012 | 320 | 0.120 |
Why?
| Influenza Vaccines | 1 | 2014 | 30 | 0.110 |
Why?
| Adaptive Immunity | 2 | 2024 | 32 | 0.110 |
Why?
| Carbon Dioxide | 2 | 2023 | 91 | 0.110 |
Why?
| Nasopharynx | 2 | 2023 | 25 | 0.110 |
Why?
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 10 | 0.110 |
Why?
| Cerebral Arterial Diseases | 1 | 2012 | 8 | 0.110 |
Why?
| Vitamin D | 1 | 2013 | 88 | 0.110 |
Why?
| Adrenal Cortex Hormones | 2 | 2024 | 94 | 0.110 |
Why?
| Ultrasonography | 1 | 2015 | 436 | 0.110 |
Why?
| Pediatrics | 1 | 2016 | 279 | 0.110 |
Why?
| Anticoagulants | 2 | 2012 | 250 | 0.110 |
Why?
| Heart Defects, Congenital | 1 | 2018 | 595 | 0.110 |
Why?
| Blood Coagulation Disorders | 1 | 2012 | 33 | 0.110 |
Why?
| Anti-Infective Agents | 1 | 2013 | 95 | 0.100 |
Why?
| Antiphospholipid Syndrome | 1 | 2012 | 9 | 0.100 |
Why?
| Enoxaparin | 1 | 2012 | 27 | 0.100 |
Why?
| Antihypertensive Agents | 1 | 2013 | 117 | 0.100 |
Why?
| Polysaccharides | 1 | 2012 | 50 | 0.100 |
Why?
| Immunomodulation | 1 | 2012 | 37 | 0.100 |
Why?
| Sensitivity and Specificity | 2 | 2019 | 861 | 0.100 |
Why?
| Bacterial Load | 1 | 2011 | 12 | 0.100 |
Why?
| Postoperative Complications | 1 | 2018 | 984 | 0.100 |
Why?
| RNA, Ribosomal | 1 | 2011 | 20 | 0.100 |
Why?
| Interferons | 2 | 2022 | 38 | 0.100 |
Why?
| Abbreviated Injury Scale | 2 | 2021 | 6 | 0.100 |
Why?
| Fetal Blood | 1 | 2012 | 68 | 0.100 |
Why?
| Pressure | 2 | 2023 | 105 | 0.100 |
Why?
| Fibrinolytic Agents | 1 | 2012 | 124 | 0.100 |
Why?
| Grief | 2 | 2021 | 9 | 0.100 |
Why?
| Suction | 1 | 2011 | 23 | 0.100 |
Why?
| Fatal Outcome | 1 | 2012 | 195 | 0.100 |
Why?
| Metagenome | 1 | 2011 | 41 | 0.100 |
Why?
| Survivors | 2 | 2022 | 126 | 0.090 |
Why?
| Stem Cells | 1 | 2012 | 171 | 0.090 |
Why?
| Phenotype | 2 | 2023 | 729 | 0.090 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2024 | 388 | 0.090 |
Why?
| Intensive Care, Neonatal | 1 | 2010 | 23 | 0.090 |
Why?
| Stroke Volume | 2 | 2021 | 116 | 0.090 |
Why?
| Clinical Competence | 2 | 2023 | 393 | 0.090 |
Why?
| Potassium | 2 | 2022 | 57 | 0.080 |
Why?
| Cytokines | 1 | 2012 | 612 | 0.080 |
Why?
| Gene Expression | 2 | 2022 | 609 | 0.080 |
Why?
| Purines | 1 | 2008 | 38 | 0.080 |
Why?
| Survival Analysis | 2 | 2022 | 653 | 0.080 |
Why?
| Diseases in Twins | 1 | 2008 | 15 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 595 | 0.080 |
Why?
| Pulmonary Wedge Pressure | 1 | 2008 | 19 | 0.080 |
Why?
| Pulmonary Edema | 1 | 2008 | 18 | 0.080 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2022 | 485 | 0.070 |
Why?
| Stroke | 1 | 2012 | 492 | 0.070 |
Why?
| Cardiovascular Diseases | 1 | 2012 | 440 | 0.070 |
Why?
| Neovascularization, Physiologic | 2 | 2012 | 68 | 0.070 |
Why?
| Cardiac Catheterization | 1 | 2008 | 201 | 0.070 |
Why?
| Cell Division | 2 | 2004 | 292 | 0.070 |
Why?
| Aorta | 2 | 2004 | 161 | 0.060 |
Why?
| RNA, Viral | 2 | 2017 | 125 | 0.060 |
Why?
| Angiopoietin-2 | 1 | 2024 | 15 | 0.060 |
Why?
| Hypocapnia | 1 | 2024 | 10 | 0.060 |
Why?
| Animals | 5 | 2020 | 13187 | 0.060 |
Why?
| Vascular Resistance | 1 | 2004 | 54 | 0.060 |
Why?
| Culture Media, Serum-Free | 1 | 2004 | 15 | 0.060 |
Why?
| Androstadienes | 1 | 2004 | 10 | 0.060 |
Why?
| Carotid Artery Injuries | 1 | 2004 | 13 | 0.060 |
Why?
| Respiratory Function Tests | 1 | 2004 | 90 | 0.060 |
Why?
| Diffuse Axonal Injury | 1 | 2023 | 2 | 0.060 |
Why?
| Oligonucleotides, Antisense | 1 | 2004 | 28 | 0.060 |
Why?
| Chromones | 1 | 2004 | 21 | 0.060 |
Why?
| Probability | 1 | 2004 | 164 | 0.060 |
Why?
| Drug Resistance, Microbial | 1 | 2024 | 46 | 0.060 |
Why?
| PTEN Phosphohydrolase | 1 | 2004 | 55 | 0.060 |
Why?
| Glycocalyx | 1 | 2023 | 2 | 0.060 |
Why?
| Chondroitin Sulfates | 1 | 2023 | 13 | 0.060 |
Why?
| Disaccharides | 1 | 2023 | 11 | 0.060 |
Why?
| Immunity, Innate | 1 | 2024 | 104 | 0.060 |
Why?
| Corpus Callosum | 1 | 2023 | 28 | 0.060 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 15 | 0.060 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2004 | 77 | 0.060 |
Why?
| Syndecan-1 | 1 | 2023 | 72 | 0.060 |
Why?
| Morpholines | 1 | 2004 | 71 | 0.060 |
Why?
| Sirolimus | 1 | 2004 | 62 | 0.060 |
Why?
| Water-Electrolyte Balance | 1 | 2023 | 19 | 0.060 |
Why?
| Cost of Illness | 1 | 2024 | 117 | 0.060 |
Why?
| Catheterization | 1 | 2004 | 96 | 0.060 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 56 | 0.060 |
Why?
| Vasoconstrictor Agents | 1 | 2024 | 84 | 0.060 |
Why?
| Proteoglycans | 1 | 2023 | 80 | 0.060 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 157 | 0.060 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 141 | 0.060 |
Why?
| Sequence Analysis, RNA | 1 | 2023 | 91 | 0.050 |
Why?
| Chemotactic Factors | 1 | 2022 | 5 | 0.050 |
Why?
| Methicillin | 1 | 2022 | 11 | 0.050 |
Why?
| Protein Processing, Post-Translational | 1 | 2004 | 171 | 0.050 |
Why?
| Sodium Bicarbonate | 1 | 2022 | 9 | 0.050 |
Why?
| Case-Control Studies | 2 | 2019 | 1131 | 0.050 |
Why?
| Rats, Sprague-Dawley | 2 | 2004 | 1597 | 0.050 |
Why?
| Phosphorylation | 1 | 2004 | 535 | 0.050 |
Why?
| Haemophilus influenzae | 1 | 2022 | 19 | 0.050 |
Why?
| Protein Kinase Inhibitors | 1 | 2004 | 204 | 0.050 |
Why?
| Hospitals | 1 | 2023 | 175 | 0.050 |
Why?
| Interferon-gamma | 1 | 2022 | 177 | 0.050 |
Why?
| Norepinephrine | 1 | 2022 | 107 | 0.050 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 391 | 0.050 |
Why?
| Complement Activation | 1 | 2021 | 42 | 0.050 |
Why?
| Patient Acuity | 1 | 2021 | 16 | 0.050 |
Why?
| Dopamine | 1 | 2022 | 171 | 0.050 |
Why?
| Injury Severity Score | 1 | 2021 | 159 | 0.050 |
Why?
| Influenza in Birds | 1 | 2020 | 1 | 0.050 |
Why?
| Birds | 1 | 2020 | 12 | 0.050 |
Why?
| Recurrence | 2 | 2012 | 652 | 0.050 |
Why?
| Registries | 1 | 2023 | 522 | 0.050 |
Why?
| Calcium | 1 | 2022 | 396 | 0.050 |
Why?
| DNA, Bacterial | 1 | 2021 | 187 | 0.050 |
Why?
| Blood Gas Analysis | 1 | 2020 | 30 | 0.050 |
Why?
| Patient Acceptance of Health Care | 1 | 2024 | 329 | 0.050 |
Why?
| Healthcare Disparities | 1 | 2024 | 257 | 0.050 |
Why?
| Seasons | 1 | 2020 | 81 | 0.050 |
Why?
| Stromal Cells | 1 | 2020 | 72 | 0.050 |
Why?
| Single-Cell Analysis | 1 | 2020 | 57 | 0.050 |
Why?
| Bicarbonates | 1 | 2020 | 17 | 0.040 |
Why?
| Endpoint Determination | 1 | 2020 | 24 | 0.040 |
Why?
| Cells, Cultured | 1 | 2004 | 1573 | 0.040 |
Why?
| American Heart Association | 1 | 2020 | 32 | 0.040 |
Why?
| Extracellular Matrix | 1 | 2020 | 111 | 0.040 |
Why?
| Rats | 2 | 2004 | 3305 | 0.040 |
Why?
| Regression Analysis | 1 | 2021 | 395 | 0.040 |
Why?
| Pilot Projects | 1 | 2022 | 699 | 0.040 |
Why?
| Developmental Disabilities | 1 | 2021 | 119 | 0.040 |
Why?
| Community-Acquired Infections | 1 | 2020 | 39 | 0.040 |
Why?
| Interferon-alpha | 1 | 2020 | 47 | 0.040 |
Why?
| Maternal Exposure | 2 | 2012 | 86 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 486 | 0.040 |
Why?
| Hematoma, Subdural | 1 | 2019 | 21 | 0.040 |
Why?
| Consensus | 1 | 2020 | 148 | 0.040 |
Why?
| Bayes Theorem | 1 | 2020 | 109 | 0.040 |
Why?
| Skull Fractures | 1 | 2019 | 17 | 0.040 |
Why?
| Cardiac Output | 1 | 2019 | 34 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2020 | 111 | 0.040 |
Why?
| Data Collection | 1 | 2020 | 279 | 0.040 |
Why?
| Intracranial Hemorrhages | 1 | 2019 | 38 | 0.040 |
Why?
| Mortality | 1 | 2020 | 99 | 0.040 |
Why?
| Family | 1 | 2020 | 170 | 0.040 |
Why?
| Amino Acid Substitution | 1 | 2019 | 82 | 0.040 |
Why?
| Creatinine | 1 | 2019 | 139 | 0.040 |
Why?
| Inflammation | 1 | 2023 | 604 | 0.040 |
Why?
| RNA, Messenger | 1 | 2022 | 1105 | 0.040 |
Why?
| Staphylococcus aureus | 1 | 2022 | 326 | 0.040 |
Why?
| Communication | 1 | 2021 | 246 | 0.040 |
Why?
| Metabolic Clearance Rate | 1 | 2019 | 68 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 2020 | 224 | 0.040 |
Why?
| Gene Expression Profiling | 2 | 2020 | 1032 | 0.040 |
Why?
| Antiviral Agents | 1 | 2020 | 173 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2018 | 84 | 0.040 |
Why?
| Comorbidity | 1 | 2020 | 615 | 0.040 |
Why?
| Glucocorticoids | 1 | 2020 | 219 | 0.040 |
Why?
| Feasibility Studies | 1 | 2019 | 375 | 0.040 |
Why?
| Middle Aged | 2 | 2024 | 12069 | 0.040 |
Why?
| Proteins | 1 | 2000 | 342 | 0.040 |
Why?
| Causality | 1 | 2017 | 44 | 0.040 |
Why?
| Point-of-Care Systems | 1 | 2018 | 56 | 0.040 |
Why?
| Genotyping Techniques | 1 | 2017 | 20 | 0.040 |
Why?
| Pandemics | 1 | 2022 | 559 | 0.040 |
Why?
| Homozygote | 1 | 2017 | 56 | 0.040 |
Why?
| Diagnosis, Differential | 1 | 2021 | 1037 | 0.040 |
Why?
| Social Class | 1 | 2018 | 94 | 0.040 |
Why?
| Linear Models | 1 | 2018 | 280 | 0.040 |
Why?
| Protein Isoforms | 1 | 2017 | 119 | 0.040 |
Why?
| Protein Binding | 1 | 2019 | 660 | 0.040 |
Why?
| Body Weight | 1 | 2019 | 513 | 0.030 |
Why?
| Depression | 1 | 2021 | 568 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2018 | 903 | 0.030 |
Why?
| National Institutes of Health (U.S.) | 1 | 2016 | 46 | 0.030 |
Why?
| Algorithms | 1 | 2019 | 615 | 0.030 |
Why?
| Models, Biological | 1 | 2019 | 727 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2018 | 549 | 0.030 |
Why?
| Child Health Services | 1 | 2016 | 77 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 658 | 0.030 |
Why?
| Orthomyxoviridae | 1 | 2014 | 3 | 0.030 |
Why?
| Immune System | 1 | 2013 | 44 | 0.030 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 44 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 825 | 0.030 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2014 | 198 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2012 | 116 | 0.020 |
Why?
| Diagnostic Imaging | 1 | 2012 | 176 | 0.020 |
Why?
| Electrocardiography | 1 | 2012 | 257 | 0.020 |
Why?
| Mice | 1 | 2020 | 5739 | 0.020 |
Why?
| Endothelial Cells | 1 | 2012 | 269 | 0.020 |
Why?
| Dietary Supplements | 1 | 2013 | 443 | 0.020 |
Why?
| Flow Cytometry | 1 | 2012 | 476 | 0.020 |
Why?
| Embryo, Mammalian | 1 | 2000 | 66 | 0.010 |
Why?
| Cloning, Molecular | 1 | 2000 | 185 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|